Business Context and Reporting Period
This Form 8-K filing by Moderna, Inc. (MRNA) reports a corporate governance event dated March 10, 2021. The filing details the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change is the expansion of the Board of Directors. The Board size was fixed at nine directors, adding a third Class III director position. Elizabeth Nabel, M.D., was appointed to this position effective March 10, 2021.
Management Commentary and Governance Details
- Appointment: Dr. Nabel was appointed to the Board and assigned to the Product Development Committee and the Nominating and Corporate Governance Committee.
- Term: She will serve until the 2021 annual meeting of stockholders on April 28, 2021, or until earlier death, resignation, or removal. She is up for election as a Class III director at that meeting.
- Compensation: Due to her prior service on the Board (2015–2020), Dr. Nabel will not receive the standard initial option grant for new directors. Instead, she received a "Prorated Annual Option Grant" based on the period from her appointment to the 2021 annual meeting. These options vest in full on the date of the annual meeting, subject to continued service.
- Relationships: The filing states there are no family relationships between Dr. Nabel and other directors or officers, and no reportable transactions under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact number of options granted in the Prorated Annual Option Grant in subsequent filings or proxy statements.
- Confirm Dr. Nabel's election status at the 2021 annual meeting of stockholders.
- Review the composition of the Product Development and Nominating and Corporate Governance Committees following this appointment.
